- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | OSR Holdings changes corporate name to OSR Health | 3 | Investing.com | ||
| Mo | OSR Health, Inc.: OSR Holdings Is Now OSR Health - A New Name That Says Exactly What We Do | 242 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / June 22, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced that it has officially changed its corporate name to OSR Health, Inc., a fresh identity that more directly... ► Artikel lesen | |
| OSR HEALTH Aktie jetzt für 0€ handeln | |||||
| 17.06. | OSR Health ändert Firmennamen - Handelssymbole an der NASDAQ bleiben unverändert | 1 | Investing.com Deutsch | ||
| 17.06. | OSR Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.06. | OSR Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.06. | OSR Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.05. | OSR Holdings to acquire VXM01 IP portfolio for $30 million | 2 | Investing.com | ||
| 27.05. | OSR Holdings, Inc.: OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction | 473 | ACCESS Newswire | Transaction Centralizes VXM01 Ownership and Long-Term Royalty Economics at the OSRH Parent Level BELLEVUE, WA / ACCESS Newswire / May 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare... ► Artikel lesen | |
| 13.05. | OSR Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | OSR Holdings rules out reverse stock split amid Nasdaq compliance efforts | 3 | Investing.com | ||
| 12.05. | OSR Holdings, Inc.: CEO Statement to Shareholders | 371 | ACCESS Newswire | A Clear Commitment: No Reverse Stock Split BELLEVUE, WA / ACCESS Newswire / May 12, 2026 / As many of our shareholders are aware, OSR Holdings filed its Preliminary Proxy Statement on Schedule PRE 14A... ► Artikel lesen | |
| 05.05. | OSR Holdings, Inc.: Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target | 532 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / May 5, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price target... ► Artikel lesen | |
| 30.04. | OSR Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.04. | OSR Holdings, Inc.: OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026 | 476 | ACCESS Newswire | OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026 BELLEVUE, WA / ACCESS Newswire / April 30, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding... ► Artikel lesen | |
| 30.04. | OSR Holdings Stock Surges Over 41% After Hours: Why Is It Moving? | 4 | Benzinga.com | ||
| 30.04. | OSR Holdings Executes $815 Million Global License Agreement For VXM01 With BCM Europe | 8 | pulse2.com | ||
| 29.04. | OSR Holdings licenses VXM01 to BCME for up to $815M in milestones | 5 | Investing.com | ||
| 29.04. | OSR Holdings, Inc.: OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe | 528 | ACCESS Newswire | Largest shareholder pledges entire equity stake as collateral for milestone obligations, reinforcing alignment with public shareholders BELLEVUE, WA / ACCESS Newswire / April 29, 2026 / OSR Holdings... ► Artikel lesen | |
| 22.04. | Yeiseok Kim wird neuer Chief Operating Officer bei OSR Holdings | - | Investing.com Deutsch | ||
| 22.04. | OSR Holdings, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,219 | +6,28 % | Druck auf Pacific Biosciences nimmt zu: Warum die Geduld der Anleger auf eine harte Probe gestellt wird | Pacific Biosciences gerät zunehmend unter Druck: Die Aktie steht nach einer "significant downward revision of revenue guidance" und dem erzwungenen Aktienrückzug eines Großaktionärs im Fokus. Für Investoren... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,901 | +4,28 % | CytomX Therapeutics, Inc. - 8-K, Current Report | ||
| CARISMA THERAPEUTICS INC | 0,028 | 0,00 % | United Immunity Acquires Macrophage Assets from Carisma Therapeutics | ||
| CAPRICOR | 26,120 | +1,01 % | Capricor Therapeutics Aktie im Aufwind: Anleger positionieren sich für FDA-Entscheidung | ||
| CORMEDIX | 7,598 | +0,48 % | CorMedix, Inc.: U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin Patent Litigation | PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 3,724 | -6,10 % | Minerva Neurosciences, Inc: Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs | Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategyBURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| REPLIMUNE | 10,165 | +1,24 % | Regenxbio, Replimune among gainers after FDA U-turn on UniQure | ||
| VALERIO THERAPEUTICS | 0,185 | 0,00 % | Valerio Therapeutics Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting | Seasoned biotech leader with deep expertise in RNA medicines, targeted delivery, and in vivo cell therapy joins to drive Valerio's next phase of innovation in precision targeted therapeutics
... ► Artikel lesen | |
| RANI THERAPEUTICS | 0,781 | +3,42 % | Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition | - Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen - - Appointed Alireza Javadi, Ph.D. as Chief Technical Officer... ► Artikel lesen | |
| IO BIOTECH | 0,048 | 0,00 % | IO Biotech Provides Corporate Update | Raymond James engaged as financial advisorReduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| ALTO NEUROSCIENCE | 26,230 | +7,24 % | H.C. Wainwright reiterates Alto Neuroscience stock rating at buy | ||
| CERO THERAPEUTICS | 0,095 | +0,11 % | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment | Fifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned cohort in ongoing Phase 1 study in hematologic malignancies... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 132,97 | +0,07 % | Apogee Therapeutics vor Übernahme: sharedealsPlus-Tipp wird zum Multibagger | Nachdem wir die Aktie von Apogee Therapeutics bereits im vergangenen Jahr zu Preisen von rund 40 US$ als heißen Buyout-Kandidaten vorgestellt hatten und sich ihr Kurs zwischenzeitlich mehr als verdoppeln... ► Artikel lesen | |
| ABSCI | 9,245 | +24,76 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| QIAGEN | 34,100 | +4,57 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen vor Zahlen zum zweiten Quartal auf "Buy" belassen. Diese dürften sich im Rahmen der eigenen Vorgaben des Diagnostikspezialisten... ► Artikel lesen |
Das Unternehmen OSR HEALTH INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,008 (-2,08 %) liegt der Kurs bei 0,354 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OSR HEALTH INC finden Sie auf Wallstreet Online.